What Controls Hepatic Uptake of PEGylated Nanoparticles?
Study question and conceptual design
Ge et al. ask how two nanoparticle properties—particle size and PEG-chain length—shape hepatic distribution and cellular uptake. The study compares PEGylated iron oxide nanoparticles in two size categories and three PEG-length categories, combining radiotracer-based in vivo SPECT/CT observations with complementary uptake analyses in primary hepatocytes (HCs), liver sinusoidal endothelial cells (LSECs), Kupffer cells (KCs), and hepatic stellate cells (HSCs). This paired design is conceptually important because whole-organ accumulation may reflect the combined behavior of several hepatic cell populations rather than a single dominant clearance cell type. The study is reported in ACS Nano (2026).
Reported findings
In vivo imaging indicated that the smaller particles initially showed renal clearance, whereas the larger particles displayed greater liver and spleen accumulation and ultimately substantial hepatic uptake. Longer PEG chains generally prolonged circulation and delayed hepatic uptake. Among the tested formulations, particles carrying 2K PEG showed the lowest hepatic accumulation, which the authors interpret as an apparent balance between circulation persistence and hepatic sequestration rather than a simple “more PEG is always better” relationship.
The in vitro results further complicated the conventional view that Kupffer cells are necessarily the principal site of nanoparticle uptake. The reported cellular pattern was approximately HCs ∼ HSCs > LSECs > KCs, although the relative ranking is specific to the tested particle set, cell models, and measurements. The authors also report that small-particle liver accumulation corresponded more closely with uptake by primary hepatocytes, while large-particle accumulation was associated with interactions involving LSECs and KCs. These observations support a heterogeneous, size-dependent model of hepatic nanoparticle handling.
What the evidence supports—and what it does not
The strongest contribution of the study is its integration of organ-level imaging with cell-type comparisons. The findings support the interpretation that nanoparticle size and surface architecture can influence both circulation behavior and the cellular composition of hepatic uptake. They also provide evidence against treating Kupffer-cell activity as a universal proxy for total liver clearance.
However, the results should not be read as a general ranking of all liver-cell types or all nanoparticle systems. The reported comparisons involve iron oxide nanoparticles, a limited size range, and three PEG-chain lengths. Uptake in isolated primary-cell contexts may not reproduce the vascular, extracellular-matrix, protein-corona, immune, and hemodynamic features of an intact liver. In addition, the supplied study summary does not provide enough information to evaluate cohort sizes, uncertainty estimates, species-specific applicability, long-term fate, or whether radiolabel behavior could differ from that of the nanoparticle itself. These boundaries make the work mechanistically informative but not by itself sufficient to predict clinical biodistribution or therapeutic performance.
Scope note on chlorpromazine
Chlorpromazine and chlorpromazine hydrochloride belong to a separate pharmacological context: the supplied product information describes chlorpromazine as a phenothiazine-class typical antipsychotic associated with dopamine receptor signaling, antiemetic activity, antipsychotic research, and schizophrenia research. Those terms are not variables examined in the cited nanoparticle study, and the supplied summary does not report chlorpromazine use. Accordingly, this paper should be interpreted as a nanomedicine and hepatic-cell-interaction study, not as evidence about chlorpromazine, dopamine D2 receptor antagonism, or antiemetic-agent activity.
Editorial assessment
Ge et al. provide a useful framework for studying nanoliver interactions as a distributed process involving particle properties and multiple hepatic cell populations. The evidence is strongest for the reported comparisons within this iron oxide nanoparticle model. Broader claims about nanoparticle clearance, safety, or translational design require additional evidence across materials, biological systems, exposure contexts, and longer-term outcomes.